Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,733 active trials43 approved drugs557 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,059 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01862718 | Fusion Guided Thermal Ablation Combined With External Beam Radiation for Hepatic Neoplasms | terminated | Phase 1 | 5 | National Institutes of Health Clinical Center (CC)NIH | 1 | Aug 15, 2022 | clinicaltrials |
| NCT01525069 | Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma | terminated | Phase 1 | 27 | Washington University School of MedicineOTHER | 1 | Aug 10, 2022 |
| clinicaltrials |
| NCT02300922 | Pretargeted Radioimmunotherapy in Metastatic Colorectal Cancer(RITCOLON) | terminated | Phase 1 / Phase 2 | 7 | Nantes University HospitalOTHER | 1 | Aug 1, 2022 | clinicaltrials |
| NCT02575339 | MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 11 | Kathy MillerOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | terminated | Phase 1 | 49 | Genocea Biosciences, Inc.INDUSTRY | 1 | Jul 15, 2022 | clinicaltrials |
| NCT02514031 | ARQ-761 Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Pancreatic Cancer | terminated | Phase 1 | 17 | University of Texas Southwestern Medical CenterOTHER | 1 | Jun 3, 2022 | clinicaltrials |
| NCT04178460 | A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment | terminated | Phase 1 | 60 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 1 | Jun 1, 2022 | clinicaltrials |
| NCT03059147 | Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular Carcinoma | terminated | Phase 1 | 7 | SignalRX Pharmaceuticals, Inc.INDUSTRY | 1 | May 18, 2022 | clinicaltrials |
| NCT04327986 | Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | May 18, 2022 | clinicaltrials |
| NCT03655613 | APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC | terminated | Phase 1 / Phase 2 | 20 | Apollomics (Australia) Pty. Ltd.INDUSTRY | 2 | May 6, 2022 | clinicaltrials |
| NCT04131192 | Gemcitabine and Z650 in Treating Patients With Metastatic or Recurrent Pancreatic Cancer | terminated | Phase 1 | 13 | Sunshine Lake Pharma Co., Ltd.INDUSTRY | 1 | May 6, 2022 | clinicaltrials |
| NCT03316222 | Study of GNS561 in Patients With Liver Cancer | terminated | Phase 1 / Phase 2 | 50 | Genoscience PharmaINDUSTRY | 3 | May 2, 2022 | clinicaltrials |
| NCT02102022 | Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 140 | Polaris GroupINDUSTRY | 6 | Apr 25, 2022 | clinicaltrials |
| NCT03294252 | Oxaliplatin in PIPAC for Nonresectable Peritoneal Metastases of Digestive Cancers(PIPOX) | terminated | Phase 1 / Phase 2 | 34 | Institut Cancerologie de l'OuestOTHER | 1 | Apr 25, 2022 | clinicaltrials |
| NCT04627142 | A Study to Test Different Doses of BI 1701963 in Combination With Irinotecan in People With Advanced Bowel Cancer With Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutation | terminated | Phase 1 | 15 | Boehringer IngelheimINDUSTRY | 1 | Apr 20, 2022 | clinicaltrials |
| NCT01198522 | Combination Therapy of L19IL2 and Gemcitabine in Advanced Pancreatic Cancer Patients | terminated | Phase 1 | 28 | Philogen S.p.A.INDUSTRY | 2 | Apr 15, 2022 | clinicaltrials |
| NCT03707028 | A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer | terminated | Phase 1 / Phase 2 | 12 | Elevar TherapeuticsINDUSTRY | 1 | Apr 11, 2022 | clinicaltrials |
| NCT02384850 | Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer(SENTINEL) | terminated | Phase 1 | 10 | GSO Global Clinical Research BVOTHER | 2 | Apr 8, 2022 | clinicaltrials |
| NCT02859415 | Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Apr 5, 2022 | clinicaltrials |
| NCT02420795 | Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | terminated | Phase 1 / Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT03300921 | A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer | terminated | Phase 1 | 3 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT03278626 | Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma | terminated | Phase 1 / Phase 2 | 12 | NYU Langone HealthOTHER | 1 | Mar 28, 2022 | clinicaltrials |
| NCT01790035 | Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer(LGG) | terminated | Phase 1 | 23 | Washington University School of MedicineOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT03735290 | A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer(ILIAD) | terminated | Phase 1 | 21 | MendusINDUSTRY | 1 | Mar 16, 2022 | clinicaltrials |
| NCT00447122 | BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer | terminated | Phase 1 | 25 | Brown UniversityOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT03875313 | Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 33 | Calithera Biosciences, IncINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT02559024 | Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer | terminated | Phase 1 | 4 | Providence Health & ServicesOTHER | 1 | Feb 14, 2022 | clinicaltrials |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | terminated | Phase 1 | 67 | MacroGenicsINDUSTRY | 3 | Feb 8, 2022 | clinicaltrials |
| NCT03637491 | A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors | terminated | Phase 1 / Phase 2 | 36 | PfizerINDUSTRY | 3 | Jan 26, 2022 | clinicaltrials |
| NCT02465593 | A Study of PEP503(Radio-enhancer) With Radiotherapy and Chemotherapy for Patients With Rectal Cancer | terminated | Phase 1 / Phase 2 | 32 | PharmaEngineINDUSTRY | 1 | Jan 11, 2022 | clinicaltrials |
| NCT01285102 | Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer | terminated | Phase 1 | 4 | Fox Chase Cancer CenterOTHER | 1 | Dec 20, 2021 | clinicaltrials |
| NCT02999893 | A Study of APR-246 in Oesophageal Cancer(APROC) | terminated | Phase 1 / Phase 2 | 5 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Dec 13, 2021 | clinicaltrials |
| NCT01134601 | A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum | terminated | Phase 1 | 1 | National Cancer Institute (NCI)NIH | 1 | Dec 1, 2021 | clinicaltrials |
| NCT04165031 | A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation | terminated | Phase 1 / Phase 2 | 5 | Eli Lilly and CompanyINDUSTRY | 2 | Nov 24, 2021 | clinicaltrials |
| NCT01324141 | Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer | terminated | Phase 1 | 6 | National Cancer Institute (NCI)NIH | 1 | Nov 23, 2021 | clinicaltrials |
| NCT02304289 | Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of Artesunate in Patients With Hepatocellular Carcinoma(DESPARTH) | terminated | Phase 1 | 2 | University Hospital, GhentOTHER | 1 | Oct 27, 2021 | clinicaltrials |
| NCT03176264 | PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer | terminated | Phase 1 | 1 | Novartis PharmaceuticalsINDUSTRY | 1 | Oct 12, 2021 | clinicaltrials |
| NCT04158349 | Intraperitoneal Oxaliplatin in Combo w IV mFOLFIRI for Peritoneal Carcinomatosis From Colorectal & Appendiceal Cancer(IPOX-FOLFIRI) | terminated | Phase 1 | 1 | University of UtahOTHER | 1 | Sep 27, 2021 | clinicaltrials |
| NCT02851004 | Special Combination of BBI608 and Pembrolizumab | terminated | Phase 1 / Phase 2 | 55 | Takayuki YoshinoOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT01805037 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas | terminated | Phase 1 / Phase 2 | 20 | Northwestern UniversityOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT02687230 | Phase 1 Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1 | terminated | Phase 1 | 15 | BioNTech Research & Development, Inc.INDUSTRY | 1 | Aug 31, 2021 | clinicaltrials |
| NCT04099277 | A Study of LY3435151 in Participants With Solid Tumors | terminated | Phase 1 | 2 | Eli Lilly and CompanyINDUSTRY | 2 | Aug 31, 2021 | clinicaltrials |
| NCT00041691 | Safety Study of 90Y-hMN14 to Treat Colorectal Cancer Patients With Limited Residual Disease After Surgery | terminated | Phase 1 | 30 | Gilead SciencesINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| NCT01335945 | Safety and Efficacy of Cryoablation for Abdominal Pain Associated With Pancreatic Cancer | terminated | Phase 1 | 14 | Boston Scientific CorporationINDUSTRY | 1 | Jul 16, 2021 | clinicaltrials |
| NCT02908451 | A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer | terminated | Phase 1 | 39 | AbGenomics B.V Taiwan BranchINDUSTRY | 2 | Jul 13, 2021 | clinicaltrials |
| NCT01784861 | VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors | terminated | Phase 1 / Phase 2 | 23 | Washington University School of MedicineOTHER | 1 | Jul 8, 2021 | clinicaltrials |
| NCT03451773 | M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas | terminated | Phase 1 / Phase 2 | 7 | National Cancer Institute (NCI)NIH | 1 | Jun 16, 2021 | clinicaltrials |
| NCT03203304 | Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer | terminated | Phase 1 | 14 | University of ChicagoOTHER | 1 | Jun 10, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Aug 15, 2022source: clinicaltrials